Your browser doesn't support javascript.
Impact of the COVID-19 pandemic on liver transplant waitlist outcome in France.
Legeai, Camille; Antoine, Corinne; Jasseron, Carine; Kerbaul, François; Dumortier, Jérôme.
  • Legeai C; Organ and Tissue Procurement and Transplantation Department, Agence de la Biomédecine, 1, Avenue du Stade de France, 93212, Saint-Denis la Plaine Cedex, France. camille.legeai@biomedecine.fr.
  • Antoine C; Organ and Tissue Procurement and Transplantation Department, Agence de la Biomédecine, 1, Avenue du Stade de France, 93212, Saint-Denis la Plaine Cedex, France.
  • Jasseron C; Organ and Tissue Procurement and Transplantation Department, Agence de la Biomédecine, 1, Avenue du Stade de France, 93212, Saint-Denis la Plaine Cedex, France.
  • Kerbaul F; Organ and Tissue Procurement and Transplantation Department, Agence de la Biomédecine, 1, Avenue du Stade de France, 93212, Saint-Denis la Plaine Cedex, France.
  • Dumortier J; Hospices Civils de Lyon, Hôpital Edouard Herriot, Unité de Transplantation Hépatique et Université Claude Bernard Lyon 1, Lyon, France.
Sci Rep ; 13(1): 9308, 2023 Jun 08.
Artículo en Inglés | MEDLINE | ID: covidwho-20238512
ABSTRACT
The objective of this study was to investigate the impact of the COVID-19 pandemic on the outcome of patients on the liver transplantation (LT) waitlist in 2020 in France, in particular, the incidence of deaths and delisting for worsening condition, depending on the allocation score component. The 2020 cohort of patients on the waiting list was compared with the 2018/2019 cohorts. 2020 saw fewer LTs than in either 2019 or 2018 (1128, 1356, and 1325, respectively), together with fewer actual brain dead donors (1355, 1729, and 1743). In 2020, deaths or delisting for worsening condition increased significantly versus 2018/2019 (subdistribution hazard ratio 1.4, 95% confidence interval [CI] 1.2-1.7), after adjustment for age, place of care, diabetes, blood type, and score component, although COVID-19-related mortality was low. This increased risk mainly concerned patients with hepatocellular carcinoma (1.52, 95% CI 1.22-1.90), with 650 MELD exception points (2.19, 95% CI 1.08-4.43), and especially those without HCC and MELD scores from 25 to 30 (3.36 [95% CI 1.82-6.18]). In conclusion, by significantly decreasing LT activity in 2020, the COVID-19 pandemic increased the number of waitlist deaths and delisting for worsening condition, and significantly more for particular components of the score, including intermediate severity cirrhosis.
Asunto(s)

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Trasplante de Hígado / Carcinoma Hepatocelular / Enfermedad Hepática en Estado Terminal / COVID-19 / Neoplasias Hepáticas Tipo de estudio: Estudio de cohorte / Estudio experimental / Estudio observacional / Estudio pronóstico Límite: Humanos Idioma: Inglés Revista: Sci Rep Año: 2023 Tipo del documento: Artículo País de afiliación: S41598-023-32680-8

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Trasplante de Hígado / Carcinoma Hepatocelular / Enfermedad Hepática en Estado Terminal / COVID-19 / Neoplasias Hepáticas Tipo de estudio: Estudio de cohorte / Estudio experimental / Estudio observacional / Estudio pronóstico Límite: Humanos Idioma: Inglés Revista: Sci Rep Año: 2023 Tipo del documento: Artículo País de afiliación: S41598-023-32680-8